A class action suit by Australian and New Zealand victims of Thalidomide against the anti-morning sickness drug's British distributor Diageo Scotland Ltd. has been settled for 89 million Australian dollars ($81 million), a lawyer said on Monday.
Timothy C. Tyson, Chairman of Aptuit LLC, announced today the appointment of Jonathan Goldman, MD as Chief Executive Officer (CEO), completing the company's senior management leadership team. Dr. Goldman will focus his efforts on the growth of Aptuit as a leading provider of outsourced services in the early development space by establishing new partnerships with clients and pursuing strategic acquisitions.
Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) has extended the initial Prescription Drug User Fee Act (PDUFA) date for its review of the Biologics License Application (BLA) for ALPROLIX™, the company’s investigational long-lasting recombinant factor IX Fc fusion protein candidate for hemophilia B.
AcelRx Pharmaceuticals, Inc. has announced that the Zalviso New Drug Application (NDA) was accepted for filing by the FDA on November 26, 2013. The acceptance for filing of the NDA indicates the FDA has determined that the application is sufficiently complete to permit a substantive review.
Tour attendees will gain insight into the latest innovations and learn about new technologies offered by vendors and internationally recognized experts that provide a platform to support manufacturing excellence, including efficiency, flexibility and reduction of overall costs.
The Supreme Court agreed Tuesday to referee another dispute over President Barack Obama's health care law, whether businesses can use religious objections to escape a requirement to cover birth control for employees.
Specialty drugmaker BTG PLC has received U.S. approval to market an injectable drug to treat patients with varicose veins. The drug, Varithena, is pharmaceutical foam dispensed from a canister device.
Bulk bag unloader systems, designed and built specifically for food and pharmaceutical processing and packaging operations, help ensure compliance with domestic and international sanitary standards.
The Delumper® 2085L Crusher breaks up lumps, crushes minerals, improves product consistency, facilitates mixing, drying and conveying and keeps process lines running smoothly.
Companies are bracing for an influx of participants in their insurance plans due to the health-care overhaul.
New York officials say a $5.8 million grant and up to $6.2 million in tax credits have figured into Bausch & Lomb's decision to expand manufacturing and distribution in Rochester, N.Y. Gov. Andrew Cuomo says Valeant Pharmaceutical International will invest $106 million to expand capacity for its subsidiary's new line of contact lenses.
At least one person in Japan has been infected with HIV from a blood transfusion. A spokesman for the Japanese Red Cross Society said Tuesday that a male donor tested positive for HIV this month.
This first episode of The Daily Dose from Pharmaceutical Processing discusses the technology driving single use systems and why this methodology has had such an impact. Two specific benefits discussed here include limiting cross-contamination risk and reducing changeover times.
A French contraceptive maker says it will begin warning women that its morning-after pill is ineffective when taken by women who weigh more than 80 kilograms (176 pounds).
Purdue Pharma L.P. announced that the FDA has accepted for review a New Drug Application (NDA) for Targiniq ER (oxycodone HCl/naloxone HCl controlled-release) Tablets CII, for the management of chronic pain. he NDA is based on the results of a 12-week, double-blind, randomized, placebo-controlled U.S. clinical trial with 600 opioid-experienced patients as well as supporting data from other clinical studies.